More than 750 cur­rent and for­mer fed­er­al health work­ers are call­ing on HHS Sec­re­tary Robert F. Kennedy Jr. to change his tune in the wake of a dead­ly shoot­ing at the CDC’s head­quar­ters in At­lanta.

The let­ter, which was re­leased Wednes­day on a new site called Save HHS, de­scribed Kennedy as “com­plic­it in dis­man­tling Amer­i­ca’s pub­lic health in­fra­struc­ture and en­dan­ger­ing the na­tion’s health by re­peat­ed­ly spread­ing in­ac­cu­rate health in­for­ma­tion.” In a sep­a­rate press re­lease, Save HHS said he is “en­dan­ger­ing lives.”

Patrick Joseph White, who opened fire at the CD­C's cam­pus and died by a self-in­flict­ed gun­shot wound, thought the Covid-19 vac­cine he re­ceived had made him sick, ac­cord­ing to news re­ports.

For­mer FDA Com­mis­sion­er Stephen Hahn has been named CEO of ra­dio­phar­ma man­u­fac­tur­er Nu­cle­us Ra­dio­Phar­ma, with the goal of ex­pand­ing the CD­MO’s foot­print.

Hahn served as FDA com­mis­sion­er be­tween 2019 and 2021 be­fore mov­ing to the po­si­tion of CEO-part­ner of Flag­ship Pi­o­neer­ing and CEO of Har­bin­ger Health. Hahn has al­so served as the chief med­ical ex­ec­u­tive at the Uni­ver­si­ty of Texas MD An­der­son Can­cer Cen­ter in Hous­ton.

Dur­ing his first year as CEO, Hahn plans to get the com­pa­ny's on­ly fa­cil­i­ty GMP-ready, as well as ex­pand its R&D ser­vices. Over the next five years, Nu­cle­us is plan­ning to “dra­mat­i­cal­ly in­crease” its man­u­fac­tur­ing foot­print.

Build­ing fa­cil­i­ties clos­er to pa­tients is cru­cial for ra­dio­ther­a­pies. Their very short half-life makes them dif­fi­cult to trans­port over long dis­tances.

Enan­ta Phar­ma­ceu­ti­cals is es­ca­lat­ing its patent bat­tle over Pfiz­er’s Covid-19 an­tivi­ral Paxlovid.

The Wa­ter­town, MA-based drug­mak­er an­nounced Wednes­day that it filed suit against Pfiz­er in the Uni­fied Patent Court of the Eu­ro­pean Union. Enan­ta al­leges that Paxlovid in­fringes its ‘265 patent based on a 2020 ap­pli­ca­tion that de­scribes “coro­n­avirus pro­tease in­hibitors in­vent­ed by Enan­ta sci­en­tists.”

Pfiz­er beat a sim­i­lar chal­lenge brought by Enan­ta in fed­er­al court in Mass­a­chu­setts, but Enan­ta filed an ap­peal in Feb­ru­ary. In Eu­rope, Enan­ta ex­pects a hear­ing with­in the court’s 12-month tar­get, and a de­ci­sion “with­in weeks there­after," the com­pa­ny said in a news re­lease.

A Pfiz­er spokesper­son told End­points News on Wednes­day that the com­pa­ny is “con­fi­dent in our IP sur­round­ing Paxlovid and will re­spond in due course in court.”

Health­care costs are ex­pect­ed to in­crease more than they have in re­cent years, ac­cord­ing to a sur­vey of large em­ploy­ers.

The em­ploy­ers ex­pect health­care costs to in­crease by a me­di­an of 9% in 2026, up from 8% in 2025, ac­cord­ing to the Busi­ness Group on Health’s an­nu­al sur­vey of 121 large em­ploy­ers pro­vid­ing health cov­er­age to a to­tal of 11.6 mil­lion peo­ple. The sur­vey was con­duct­ed be­tween June and Ju­ly. Af­ter changes to plan de­signs, the in­crease is still ex­pect­ed to go up 7.6%.

Ex­pen­sive ther­a­pies, in­clud­ing GLP-1 med­ica­tions, are dri­ving that in­crease, ac­cord­ing to the sur­vey.

While the med­ica­tions have shown they’re clin­i­cal­ly ef­fec­tive, “they al­so con­tin­ue to as­tound and stress from a cost per­spec­tive,” Ellen Kel­say, the group’s CEO, said Tues­day on a press call. In 2026, 73% of em­ploy­ers sur­veyed said they in­tend to cov­er GLP-1s for obe­si­ty, up from 67% the year be­fore.